RhAPP

🔬 Rheumatology Advanced Practice Providers
🧬 #CME updates for a rich interaction and exchange of ideas between NPs, PAs, & PharmDs #RhAPP

[RhAPP @RheumAPP]

Part 2 of the Across the Rheum podcast is live! Dr. Sergio Schwartzman continues the three-part series on the IL-23 paradigm in PsA, joined by Jessica Farrell, PharmD, and Dr. Monica Schwarzman.

Watch now & Stay tuned for Part 3!: https://t.co/b1SgsmcAUH

[RhAPP @RheumAPP]

HPP is rare and easy to miss 🔎.

In this Journal Club, Holly Reid, APN, CPNP, MS breaks down new diagnostic criteria for hypophosphatasia and why early recognition matters.

🎧: https://t.co/uNXkCPHD6y

[RhAPP @RheumAPP]

What could be next for juvenile psoriatic arthritis?👀

Brandon Ko, APRN, DNP explores the potential role of guselkumab, unpacking the FDA submission, pediatric evidence, and how this therapy may change treatment sequencing in young patients.

Watch now!: https://t.co/QD7a7sUXm5

[RhAPP @RheumAPP]

Across the Rheum is here!🎙️

Episode 1 kicks off a new podcast series diving into the IL-23 pathway in psoriatic arthritis—breaking down the immunology, why IL-23 matters, and how it’s shaping modern treatment decisions.

Watch now!: https://t.co/9iuToOV0Sr

[RhAPP @RheumAPP]

In this episode, Amanda Mixon and pediatric rheumatology expert Brandon Ko break down the subtle signs of hypophosphatasia in kids—and the low ALP clue you don’t want to miss. A quick, practical listen for APPs and primary care clinicians.

Watch: https://t.co/WPjT78QrsJ

[RhAPP @RheumAPP]

Not all IL-23 inhibitors are the same—and this episode explains why 🌟

Amanda Mixon and Audrey Gibson unpack real-world differences, patient selection, and how IL-23 therapies fit into psoriatic disease management.

Watch here!: https://t.co/CavpNPwfBM

[RhAPP @RheumAPP]

HPP is rare—but often missed.
In this FAQ, Brandon Ko, APRN breaks down the subtle signs of hypophosphatasia across pediatrics and adults, including low alkaline phosphatase and early skeletal clues clinicians shouldn’t ignore.

Watch now!: https://t.co/09JUEN7vub

[RhAPP @RheumAPP]

Can binding behavior influence the effectiveness of an IL-23 inhibitor? 👀

Danielle Gatti Palumbo, PharmD breaks down new research on how guselkumab’s unique Fc-domain interactions may enhance IL-23 neutralization.

Watch now!: https://t.co/wOLp09UiZ2

[RhAPP @RheumAPP]

We’re excited to welcome Lisa Asfahani, PA-C and Amanda Mixon, PA-C as speakers at the upcoming RhAPP Regional in San Diego on January 16. Don’t miss this opportunity to connect and learn with fellow rheumatology APPs!

Register here: https://t.co/HtbW5Z77uw

[RhAPP @RheumAPP]

Could low ALP be the missing clue? 🤔 Watch Heather Mambretti, PA-C explain how hypophosphatasia is diagnosed and what labs clinicians shouldn’t miss.

Tune in: https://t.co/G3LABqWKoY

[RhAPP @RheumAPP]

What do CD64 and IL-23 have in common—and why does that connection matter across joints, skin, and gut? 🖐️

Lindsay Tom, PA-C, breaks down this emerging pathway and what it could mean for understanding disease activity in IMIDs.

Learn here!: https://t.co/8tlFqmncMd

[RhAPP @RheumAPP]

CD64 isn’t just another receptor—it’s a key player in inflammation!
Watch Lindsay Tom, PA-C, simplify how CD64 connects innate and adaptive immunity and why it matters in rheumatology care.

Watch here!: https://t.co/62I77WRLtL

[RhAPP @RheumAPP]

Two APPs. One specialty. A growing impact.

Hear how pediatric rheumatology APPs are expanding access to care and building confidence through community and education:https://t.co/Lj7VGuIRJl

[RhAPP @RheumAPP]

Two mechanisms. One target. 🎯

Audrey Gibson, PA-C, simplifies how guselkumab addresses IL-23–driven inflammation in a way that’s easy to understand and clinically relevant.

See it in action: https://t.co/wLbKHW72Jw

[RhAPP @RheumAPP]

Step Up to Rheumatology = 65 hours of education for APPs, by APPs 📘
Designed to build knowledge, confidence, and community in rheumatology care.

Sign up here!: https://t.co/qS1WG1SOoX

#Rheumatology #APPs #MedicalEducation

[RhAPP @RheumAPP]

Ever wonder why the mvdH-S score keeps showing up in PsA trials?
William Saalfeld, NP, breaks down why it’s still the gold standard for detecting meaningful structural change 🔍

Learn here: https://t.co/QDUjwIRmC0

[RhAPP @RheumAPP]

RhAPP is excited to present a new virtual symposium, CAR-T in Lupus: A New Era in Treatment and Trial Engagement on January 29, 2026 at 8:00 PM ET.

[RhAPP @RheumAPP]

San Diego, we’re coming your way!

Registration is officially open for the upcoming RhAPP Regional. Don’t miss this day of expert-led rheumatology education for APPs: https://t.co/HtbW5Z77uw

[RhAPP @RheumAPP]

Not all PsA trials are built the same📊

Find out how APEX improved our understanding of structural damage risk—fast, clear, and explained by William Saalfeld, NP: https://t.co/9ebpAO2wGa

[RhAPP @RheumAPP]

Talking about obesity isn’t easy—but it can be transformative.

In this cross-specialty episode, APP leaders share how to approach weight conversations with compassion, reduce stigma, and help patients take meaningful steps toward better health.

👉 : https://t.co/siIUIjsoSx